Cipla

Cipla Limited

Type	Public
Traded as	BSE: 500087 NSE: CIPLA BSE SENSEX Constituent
Industry	Pharmaceuticals
Founded	1935
Headquarters	Mumbai, Maharashtra, India
Key people	Y. K. Hamied (CMD), Chairman
Products	Pharmaceuticals and diagnostics
Revenue	69775.0 million (US$1.3 billion) (2012)
Net income	11.23 billion (US$210 million) (2012)
Employees	over 16,000
Website	www.cipla.com

Cipla Limited is pharmaceutical company based in Mumbai, India. It has pioneered the manufacture of low-cost anti-AIDS drugs for HIV-positive patients in developing countries. It has played a similarly prominent role in expanding access to drugs to fight influenza, respiratory disease and cancer. Founded by nationalist Indian scientist Khwaja Abdul Hamied as The Chemical, Industrial & Pharmaceutical Laboratories in 1935, Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions

Cipla received the Thomson Reuters India Innovation Award in 2012.

Company Profile

Founded prior to Indian independence by Khwaja Abdul Hamied on the principle that India needed to become self-sufficient in supplying medicine to its people, Cipla has always emphasized self-reliance and the right of all people to health and access to medicine, regardless of their economic circumstances or where in the world they happen to live. The company has become well known internationally for its dedication to working according to these values and prioritizing a socially-conscious approach to its operations.

Apart from its presence in the Indian market, Cipla also has an export market and exports to more than 185 countries.

Cipla cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.

HIV/AIDS medication

Cipla is the world's largest manufacturer of antiretroviral drugs (ARVs) to fight HIV/AIDS, as measured by units produced and distributed (multinational brand-name drugs are much more expensive, so in money terms Cipla medicines are probably somewhere down the list). Roughly 40 percent of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs.

In February, 2001, Cipla stunned the HIV/AIDS and public health communities by announcing it would make its triple cocktail of antiretroviral drugs available in developing countries for $350 per patient per year, a tiny fraction of the prices prevailing internationally at the time. Ten years later, looking back on the decade of rapid growth in access which ensued, the Journal of the International AIDS Society (IAS) would write:

Cipla’s dramatic price reduction, which received widespread media attention, hammered the message home that many of the multinational drug companies were abusing their market monopoly in the face of a catastrophic human disaster.

Indian law from 1972 until 2005 allowed no (end-product) patents on drugs, and provided for compulsory licensing, Cipla was able to manufacture medicines which enjoyed patent monopoly in certain other countries (particularly those where large, multinational pharmaceutical companies are based). By doing so, as well as by making an executive decision not to make profits on AIDS medication, Cipla reduced the cost of providing antiretrovirals to AIDS patients from $12,000 and beyond (monopoly prices charged by international pharma conglomerates) down to under $100 per year. While this sum remains out of reach for many millions of people in Third World countries, government and charitable sources often are in a position to make up the difference for destitute patients.

Cipla also pioneered a three-in-one tablet called Triomune containing a fixed-dose combination (FDC) of three ARVs (Lamivudine, stavudine and Nevirapine), something difficult elsewhere because the three patents were held by different companies. Another popular fixed-dose combination is produced under the name Duovir-N. This contains Lamivudine, Zidovudine and Nevirapine. Cipla manufactures generic versions of many of the most commonly prescribed anti-retroviral medication in the market, and is a highly capable manufacturer in its own right. This innovation made ARVs far more accessible and easy-to-take for patients everywhere, but particularly in poor- and middle-income countries, where the vast majority of people on anti-retroviral therapy (ART) now take such combination pills.

Cipla was among the first companies to register AIDS drugs under the US relief program PEPFAR. It has also been a major supplier of ARVs to the Clinton Foundation's HIV/AIDS Initiative, which has negotiated low-cost drug supplies for numerous developing countries.

Through its breakthrough price offers to developing country governments and leading NGOs such as Doctors Without Borders (MSF) and Oxfam, along with its keen participation in PEPFAR, the Global Fund, the Clinton Foundation's HIV/AIDS Initiative and other major donor programs fighting HIV/AIDS in Africa and elsewhere in the resource-poor world, Cipla has played an unparalleled leadership role in ensuring access to antiretroviral treatment (ART) rose from under 10,000 on the entire African continent at the time of its $350 per patient per year offer in 2001, to over 8 million in the developing world by 2012.

Antiflu and Virenza

In December 2008, Cipla won a court case in India allowing it to manufacture a cheaper generic version of oseltamivir, marketed by Hoffmann-La Roche (Roche) under the trade name Tamiflu, under the Cipla tradename Antiflu. In May 2009, Cipla won approval from the World Health Organization certifying that its drug Antiflu was as effective as Tamiflu, and Antiflu is included in the World Health Organization list of prequalified medicinal products.

Cipla announced that Oseltamivir 75 mg capsules marketed as `Antiflu` by the company has been included in the World Health Organization (WHO) list of prequalified medicinal products (PMP).

Oseltamivir is indicated for use in the treatment of influenza A (H1N1) infection commonly known as swine flu.

Cipla also produces a generic version of zanamivir, marketed by Glaxo under the trade name Relenza, under the Cipla tradename Virenza.

The New York Times reported that the government of Saudi Arabia purchased stockpiles of Antiflu in preparation for Hajj in late 2009, fearing an outbreak of flu among Hajjis arriving from all parts of the world.

The firm announced the launch of the drug under the name "Antiflu" on 11 November 2009 to be sold as a category X drug, strictly under prescription.

Cancer medications

In May 2012, Cipla made headlines worldwide by slashing prices on several cancer drugs previously priced far out of reach to the vast majority of the world's population (cancer drugs are generally the most expensive category of pharmaceutical). The Wall Street Journal quoted Cipla chairperson Yusuf Hamied as saying: "We had taken the lead to provide affordable medicine for AIDS and I think the time has now come -- 10 years later -- when we do a similar thing for cancer." The revised prices averaged roughly 75% less than the previous ones, and Hamied announced plans to similarly reduce prices on the full range of cancer drugs made by Cipla. The move was expected to prompt significant price drops from other producers, providing access to medicine and saving many millions of cancer patients unnecessary suffering and/or death.

Other drugs

Cipla also has a product range comprising antibiotics, anti-bacterials, anti-asthmatics, anthelmintics, anti-ulcerants, oncology, corticosteroids, nutritional supplements and cardiovascular drugs. The company has at least nine different prescription drugs registered with the US FDA. Active in the anti-bacterial and anti-asthmatic segments, Cipla was the first in Asia to launch a non-CFC metered dose inhaler.

In a September 2011 article, The New York Times discussed Cipla's efforts to radically lower costs of biotech drugs for cancer, diabetes and other noncommunicable diseases, and, referencing the leading role the company had played in getting low-cost AIDS drugs to developing world, the Times opined:

In retrospect, the battle 10 years ago over AIDS medicines was a small skirmish compared with the one likely to erupt over cancer, diabetes and heart medicines. The AIDS drug market was never a major moneymaker for global drug giants, while cancer and diabetes drugs are central to the companies’ very survival.

Milestones

• 1935

Dr K A Hamied sets up "The Chemical, Industrial and Pharmaceutical Laboratories Ltd." in a rented bungalow at Bombay Central.

• 1941

As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities to the war effort.

• 1952

Sets up first research division for attaining self-sufficiency in technological development.

• 1960

Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products.

• 1968

Cipla manufactures ampicillin for the first time in the country.

• 1972

Starts Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants.

• 1976

Cipla launches medicinal aerosols for asthma.

• 1980

Wins Chemexcil Award for Excellence for exports.

• 1982

Fourth factory begins operations at Patalganga, Maharashtra.

• 1984

Develops anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Wins Sir P C Ray Award for developing inhouse technology for indigenous manufacture of a number of basic drugs.

• 1985

US FDA approves Cipla's bulk drug manufacturing facilities.

• 1988

Cipla wins National Award for Successful Commercialization of Publicly Funded R&D.

• 1991

Launches etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. The company pioneers the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad.

• 1994

Cipla's fifth factory begins commercial production at Kurkumbh, Maharashtra.

• 1997

Launches transparent Rotahaler, the world's first such dry powder inhaler device now patented by Cipla in India and abroad. The palliative cancer care centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune.

• 1998

Launches lamivudine, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched).

• 1999

Launches Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child.

• 2000

Cipla became the first company, outside the USA and Europe to launch CFC-free inhalers – ten years before the deadline to phase out use of CFC in medicinal products.

• 2001

Cipla announces it is prepared to supply a triple antiretroviral (ARV) combination for $350 per patient per year in poor countries. Prices for equivalent combinations at the time ranged up to over $15,000 per year in price.

• 2002

Four state-of-the-art manufacturing facilities set up in Goa in a record time of less than twelve months.

• 2003

Launches TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Commissioned second phase of manufacturing operations at Goa.

• 2005

Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh.

• 2007

Set-up state-of-the-art facility for manufacture of formulations at Sikkim.

• 2010

Set up state-of-the-art facility for manufacture of formulations at Indore.

• 2012

Announces price cuts averaging 75% on a range of complex cancer drugs.

Receives 2012 Thomson Reuters India Innovation Award

See also

• Pharmaceutical industry in India

External links

• Home page
• CIPLA- India's No:1 Pharma Company